Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Morris, M. [1 ]
Vogelzang, N. J. [2 ]
Sartor, O. [3 ]
Armour, A. [4 ]
Groaning, M. [5 ]
Messmann, R. [6 ]
Robarts, A. [7 ]
Petrylak, D. P. [8 ]
Tolcher, A. [9 ]
Gordon, M. S. [10 ]
Babiker, H. [11 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[2] Comprehens Canc Ctr Nevada, Med Oncol, Las Vegas, NV USA
[3] Tulane Univ, Oncol, New Orleans, LA 70118 USA
[4] Endocyte Inc, Med, Indianapolis, IN USA
[5] Endocyte, Clin, Indianapolis, IN USA
[6] Endocyte, Med Oncol, W Lafayette, IN USA
[7] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[8] Yale Univ, Sch Med, Med Oncol, New Haven, CT USA
[9] START, Med Oncol, San Antonio, TX USA
[10] HonorHlth Res Inst, Med Oncol, Scottsdale, AZ USA
[11] Univ Arizona, Ctr Comprehens Canc, Med Oncol, Tucson, AZ USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
793PD
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Morris, Michael J.
    Petrylak, Daniel Peter
    Sartor, A. Oliver
    Vogelzang, Nicholas J.
    Groaning, Michael
    Ejadi, Samuel
    Tolcher, Anthony W.
    Babiker, Hani M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Ejadi, S.
    Vogelzang, N.
    Sartor, A.
    Clark, R.
    Tolcher, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S74 - S75
  • [3] Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC): Study
    Morris, M. J.
    Vogelzang, N. J.
    Sartor, O.
    Armour, A.
    Petrylak, D.
    Tolcher, A.
    Ejadi, S.
    Babiker, H. M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Phase 1 study of the PSMA-tubulysin small-molecule drug conjugate EC1169 in pts with metastatic castrate-resistant prostate cancer (mCRPC)
    Ejadi, Samuel
    Vogelzang, Nicholas J.
    Sartor, A. Oliver
    Habbe, Andrew
    Binh Nguyen
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1 169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Morris, Michael J.
    Vogelzang, NicholasJ.
    Sartor, Oliver
    Armour, Alison
    Groaning, Michael
    Robarts, Adam
    Petrylak, Daniel Peter
    Tolcher, Anthony W.
    Gordon, Michael S.
    Babiker, Hani M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Morris, M. J.
    Vogelzang, N. J.
    Sartor, O.
    Armour, A.
    Messmann, R.
    Groaning, M.
    Robarts, A.
    Tolcher, A. W.
    Gordon, M.
    Babiker, H. M.
    Kuo, P.
    Kearney, M.
    Jendrisak, A.
    Wang, Y.
    Landers, M.
    Petrylak, D. P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] A PSMA-targeted doxorubicin small-molecule drug conjugate
    Yoon, Hosog
    Savoy, Emily A.
    Mesbahi, Nooshin
    Hendricksen, Aaron T.
    March, Gabrielle L.
    Fulton, Melody D.
    Backer, Brian S.
    Berkman, Clifford E.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2024, 104
  • [8] A PH 1 STUDY OF 2 DIFFERENT SCHEDULES OF THE PSMA-TUBULYSIN SMALL-MOLECULE DRUG CONJUGATE EC1169 IN PTS WITH REC MET CAST-RESIST PC (MCRPC)
    Tolcher, A.
    Ejadi, S.
    Sartor, A. O.
    Nguyen, B.
    Habbe, A.
    Vogelzang, N.
    ANNALS OF ONCOLOGY, 2015, 26 : 17 - 17
  • [9] PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs.
    Morris, Michael J.
    Vogelzang, Nicholas J.
    Sartor, A. Oliver
    Armour, Alison A.
    Messmann, Richard Adam
    Groaning, Michael
    Robarts, Adam
    Tolcher, Anthony W.
    Gordon, Michael S.
    Babiker, Hani M.
    Kuo, Phillip
    Kearney, Megan
    Jendrisak, Adam
    Wang, Yipeng
    Landers, Mark Andrew
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [10] Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Sandhu, Gurprataap Singh
    Parikh, Rahul Atul
    Appleman, Leonard Joseph
    Friedland, David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
12345